Market-Moving Exclusives

Telomir Pharmaceuticals Inc. (NASDAQ:TELO) on Thursday released new preclinical data for its lead candidate, Telomir-1. The data demonstrated that Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a...

Fintech mortgage lender Beeline Holdings (NASDAQ:BLNE) announced Wednesday the upcoming launch of a new home equity access product that allows homeowners to convert a portion of their home equity into immediate cash without incurring debt or monthly payments. Beeline has partnered with a company ("...

Vivakor, Inc’s (NASDAQ:VIVK) announced Tuesday that its growth strategy is anchored in the Permian and Eagle Ford Basins, where the company is positioned to expand its integrated crude oil storage, logistics, and marketing value chains. Vivakor said it owns and operates 10 strategically...

Vivakor, Inc (NASDAQ:VIVK) announced on Friday that its Board of Directors has approved a plan to issue a special dividend to Vivakor shareholders. Vivakor currently holds 206,595 (approximately 13.5% of the outstanding common) shares of Adapti, Inc (OTC:BRZLD), a company that manages the marketing...

SKYX Platforms Corp. (NASDAQ:SKYX), a smart home tech firm with over 97 patents, announced a major partnership Wednesday with a $3 billion, 63-acre smart city development in Miami's Little River District. The 63-acre mixed-use urban project, led by SG Holdings (a joint venture of Swerdlow Group,...

On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced that it had secured $3 million in equity financing through a direct investment by The Bayshore Trust, the company's largest shareholder. The transaction involved the purchase of 1 million restricted shares of the company's common...

GT Biopharma, Inc. (NASDAQ:GTBP) announced Monday that it has successfully completed dosing in Cohort 1 and started dosing in Cohort 2 of its Phase 1 dose escalation trial for GTB-3650. The therapy is a second-generation TriKE therapeutic targeting relapsed or refractory CD33-expressing hematologic...

Channel Therapeutics Corporation (NYSE:CHRO) announced on Wednesday that it has achieved its predefined endpoints in two preclinical animal models for eye drop formulations (CT2000) for acute ocular and chronic ocular surface pain commonly associated with dry eye disease.  "We are very pleased...

Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Tuesday reported a third quarter 2025 loss of 44 cents per share, down from a loss of $1.43 a year ago. The noninvasive testing solutions provider reported sales of $728.87 thousand, down from $823.80 thousand a year ago. Total revenues increased 20%...

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In...

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC). The biomarker-...

DeFi Development Corp (NASDAQ:DFDV) announced on Monday that it had purchased 172,670 Solana (CRYPTO: SOL/USD) at an average purchase price of $136.81, valued at approximately $23.6 million. This marks the company's 10th Solana purchase under its digital asset treasury strategy and its largest...

Inuvo, Inc. (NYSE:INUV) announced its financial results for the first quarter ended March 31, 2025, on Friday. Revenue climbed 57% year-over-year to $26.7 million, marking the highest revenue in the company’s history. The analyst consensus estimate was $23.7 million. A 61% increase within...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek the U.S. Food and Drug Administration (FDA) guidance on the Phase 3 clinical trial for AD04. The...

Mira Pharmaceuticals, Inc.’s (NASDAQ:MIRA) Board of Directors unanimously approved on Thursday the planned acquisition of SKNY Pharmaceuticals, Inc., following the completion of independent valuation reports on both companies. In March,  MIRA Pharmaceuticals signed a binding letter of...